Date | Title | Description | Source |
23.12.2022 | Adaptimmune Announces Initiation of Biologics License Applic... | - Afami-cel has the potential to be the first approved engineered TCR T-cell therapy for a solid tum... | einpresswi... |
04.10.2022 | ROTH Capital Partners to Host Inaugural Healthcare Opportuni... | Event to feature company presentations and one-on-one meetings between institutional investors and s... | einpresswi... |
15.09.2022 | Sarcoma Foundation of America Honors Adaptimmune Therapeutic... | Adaptimmune Therapeutics has been selected to receive the 2022 Vision of Hope Award during SFA’s Sta... | einpresswi... |
15.11.2021 | Here’s Why Roche Stock May Continue To Trend Higher | Logo on building exterior at the Silicon Valley headquarters of pharmaceutical company Roche, Santa ... | forbes.com... |
08.09.2021 | Covid-19 roundup: Gates Foundation, Exscientia team up ... | UK-based AI discovery outfit Exscientia has signed its name to a $70 million collaboratio... | endpts.com... |
08.09.2021 | Merck KGaA entrusts secretive startup with a mid-stage ... | A secretive French biotech has imported a drug from Germany’s Merck KGaA that will leapfrog th... | endpts.com... |
08.09.2021 | As bluebird plans its big split, rare disease head Andrew... | As Nick Leschly counts down his final month as chief bluebird — before taking on the new role of... | endpts.com... |
08.09.2021 | A few months into his new role at Attralus, ex-Purdue chi... | Cancer player MacroGenics scored a big win with its full approval for anti-HER2 drug Margenza last w... | endpts.com... |
08.09.2021 | Looking for fresh start following a Duchenne disaster, ... | The leaders of Catabasis Pharmaceuticals have decreed that the biotech’s name is no more. Cat... | endpts.com... |
08.09.2021 | A few months into his new role at Attralus, ex-Purdue chi... | Months after Bay Area startup Attralus tapped Mark Timney to its helm, the ex-Purdue Pharma ch... | endpts.com... |
08.09.2021 | A few months into his new role at Attralus, ex-Purdue chi... | Tachi is gone, but his legacy biotechs are continuing to make news.
This morning it’s the newly born... | endpts.com... |
08.09.2021 | Years after Pfizer passed on a buyout option, AM-Pharma... | A couple of years ago, Pfizer passed on an option to buy out AM-Pharma and its recombinant hu... | endpts.com... |
08.09.2021 | Moderna surfaces as the first partner for Jim Wilson's r... | Top biopharma execs from Merck, Eli Lilly, Takeda and industry lobbying group PhRMA tried their best... | endpts.com... |
08.09.2021 | 'Like a kid in a candy shop': Michael Ehlers gets behind R... | Nathaniel Wang
Nathaniel Wang and Andrew Geall spent years working on self-replicating RNAs at S... | endpts.com... |
08.09.2021 | With industry's blessing, FDA launches novel excipie... | The FDA on Tuesday launched a new pilot program that will initially review four novel excip... | endpts.com... |
08.09.2021 | Moderna surfaces as the first partner for Jim Wilson's r... | A week after Jim Wilson and Alex Karnal debuted their Tachi Yamada-inspired nonprofit aimed... | endpts.com... |
08.09.2021 | Months after landing Canadian site from government, Re... | Bob Nelsen
Bob Nelsen’s latest project, dreamed up out of anger, has been focused on becoming th... | endpts.com... |
07.09.2021 | There's a new anti-aging upstart in town — and it's repo... | Going to space wasn’t enough. Middle-aged billionaire Jeff Bezos wants to extend human life —... | endpts.com... |
07.09.2021 | Exelixis mourns the deaths of two longtime executives... | Exelixis is grieving the loss of two longtime executives this week, one of whom succumbed to... | endpts.com... |
07.09.2021 | Doubling down on need for mRNA vaccines and mAbs, Avanto... | Acquisition-happy manufacturer Avantor has positioned itself at the front of the battle... | endpts.com... |
07.09.2021 | There's a new anti-aging upstart in town — and it's repo... | Despite its standing as pharma’s biggest cancer player, Roche has mostly stood pat on next-gen cell ... | endpts.com... |
07.09.2021 | Food or drug? FDA blasts Flagship-backed microbiome play... | Hours after the FDA wrapped its marathon listening session on the safety risks of gene therapy, BioM... | endpts.com... |
07.09.2021 | Vaccitech makes short move to new headquarters; Entero... | Oxford biotech Vaccitech is moving headquarters — but only about 20 minutes away.
Vaccitech ... | endpts.com... |
07.09.2021 | As tezepelumab awaits FDA decision, Amgen and AstraZen... | The UK’s MHRA may have to lay off about 300 of its 1,200 employees, thanks to a decline in income du... | endpts.com... |
07.09.2021 | There's a new anti-aging upstart in town — and it's repo... | Researchers and executives hoping that the FDA’s two-day hearing on gene therapy would offer a clear... | endpts.com... |
13.02.2021 | Another Keytruda combo tops standard of care in advanc... | It makes sense to join forces with your partner’s owner.
Japan’s Astellas Pharma is tying up with UK... | endpts.com... |
01.06.2020 | Adaptimmune’s ASCO data for cell therapy in sarcoma spark op... | The company announced data from its study of the TCR, which targets MAGE-A4 in several solid tumors,... | medcitynew... |
15.01.2020 | Astellas partners with Adaptimmune in latest move into cell ... | Most TCRs that have been developed are HLA-restricted, meaning they can only be used in patients wit... | medcitynew... |
28.08.2019 | Celgene invests $75M in cell therapy company Immatics as par... | The deal includes a $75 million investment in the company by Celgene. Immatics would develop TCRs ag... | medcitynew... |
22.07.2019 | Pact Pharma enrolls first patients in Phase Ia/Ib solid tumo... | “These exciting results open a bold new frontier for directing a person’s own immune system to treat... | medcitynew... |
06.05.2019 | Esperion shares surge as FDA waves off panel review; Ad... | Derek Archila
→ Esperion got a 15% bump on its stock price $ESPR this morning after the biote... | endpts.com... |
14.12.2018 | Shinichi Tamura reclaims the throne at Sosei; Jeff Abbey ... | → Jeff Abbey is jumping to the helm of Belgium’s Novadip Biosciences after leading Argos Ther... | endpts.com... |
05.09.2018 | What's up at Immunocore?; Pfizer nabs a key 'breakthroug... | → What’s up at Immunocore? Vantage is reporting that Immunocore’s chief strategy officer ... | endpts.com... |
31.10.2016 | What’s on Sanofi’s M&A list now that Medivation is gon... | As we’ve said before at Endpoints News, this has been a rough year for Sanofi $SNY. Now that Medi... | endpts.com... |
27.10.2016 | GSK dumps a late-stage HIV drug; MIT offers support for te... | Andrew Witty, GSK
GlaxoSmithKline didn’t just kill losmapimod on Wednesday. The pharma gian... | endpts.com... |
29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
07.05.2015 | Bill and Melinda Gates Foundation putting $75M toward diseas... | LIFE SCIENCE
Adaptimmune, a UK-based biotech using T-cell therapy to treat cancer and infectious dis... | medcitynew... |
02.02.2015 | OrbiMed draws in more healthcare strategics in nearly $1 bil... | A dozen leading medical research and healthcare institutions contributed to the royalty and credit f... | medcitynew... |
17.10.2014 | Report: Funding in runup to biotech and medical device IPOs ... | There were 23 venture-backed IPOs in the third quarter and 18 of them were biotech and medical devic... | medcitynew... |
25.09.2014 | Adaptimmune Raises $104m in Venture Capital | Adaptimmune, an Oxford, UK-based biotechnology company, raised $104m in venture capital.
The round w... | finsmes.co... |
20.09.2011 | Adaptimmune announces new Board appointments as clinical pro... | Adaptimmune announces new Board appointments as clinical programmes get underway
20-09-2011
Adaptimm... | cambridgen... |
14.06.2011 | Adaptimmune opens Phase I/II clinical trial for metastatic m... | Adaptimmune opens Phase I/II clinical trial for metastatic melanoma at US university
14-06-2011
Adap... | cambridgen... |
08.03.2011 | Adaptimmune announces launch of US subsidiary and appointmen... | Adaptimmune announces launch of US subsidiary and appointment of Gwen Binder-Scholl as VP...
08-03-2... | cambridgen... |
- | Report: Funding in runup to biotech and medical device IPOs ... | The initial public offering window continues to draw a steady stream of investment from venture and ... | medcitynew... |
- | Bill and Melinda Gates Foundation putting $75M toward diseas... | TOP STORIES
The Bill and Melinda Gates Foundation is investing up to $75 million in a network of dis... | medcitynew... |
- | Astellas partners with Adaptimmune in latest move into cell ... | Although the two CAR-T cell therapies that the Food and Drug Administration approved in 2017 remain ... | medcitynew... |
- | Pact Pharma enrolls first patients in Phase Ia/Ib solid tumo... | A company developing cell therapies in oncology has started dosing patients in an early-stage clinic... | medcitynew... |
- | OrbiMed draws in more healthcare strategics in nearly $1 bil... | Healthcare investor OrbiMed announced its second debt and royalty fund on Monday and continued to ex... | medcitynew... |
- | Adaptimmune’s ASCO data for cell therapy in sarcoma spark op... | Data from patients with a form of connective-tissue cancer who participated in a Phase I study of an... | medcitynew... |
- | Celgene invests $75M in cell therapy company Immatics as par... | A large biotech company is pouring tens of millions of dollars into a German firm under a partnershi... | medcitynew... |